A Cohort Study of Pregnancy and Fetal Complications Among Patients with Rheumatologic Disorders
- PMID: 40390969
- PMCID: PMC12085536
- DOI: 10.1007/s13224-024-01974-w
A Cohort Study of Pregnancy and Fetal Complications Among Patients with Rheumatologic Disorders
Abstract
Objective: We aim to investigate the maternal and fetal complications among women with rheumatic diseases (RDs) and evaluate the risk factors for adverse pregnancy outcomes.
Methods: In this cohort study, 241 women (comprising 401 pregnancies) who were diagnosed with RDs and sought treatment between 2016 and 2021 were evaluated and followed up for a duration of two years. Clinical backgrounds, pregnancy history, medication usage, immunological characteristics, and pregnancy outcomes were analyzed. Risk assessment for adverse outcomes in RDs was performed using binary logistic regression.
Results: The study revealed a 38.2% miscarriage rate and 56.9% live birth rate among 401 pregnancies. Maternal adverse events included gestational hypertension (4.7%), gestational diabetes mellitus (2.7%), and (pre)eclampsia (1.7%). Fetal adverse outcomes consisted of miscarriages in 153 (38.2%), low birth weight in 45 (11.2%), preterm labor in 20 (5%), and fetal heart block in eight (2%). Risk factors associated with adverse fetal outcomes were systemic lupus erythematosus (SLE) (OR 8.24, 95% CI 1.65-41.15), vasculitis (OR 8.06, 95% CI 2.7-24.02), SLE/Sjögren's syndrome (SS) overlap (OR 4.05, 95% CI 1.8-9.11), and history of hypothyroidism (OR 2.81, 95% CI 1.52-5.2).
Conclusion: RDs exerted a negative impact on pregnancy outcomes, resulting in complications for both the mother and the fetus. Our study emphasizes the significance of effectively managing RDs during pregnancy, with particular emphasis on SLE, vasculitis, and the overlap of SS with SLE. To improve pregnancy outcomes, a multidisciplinary approach, early identification of high-risk patients, and the implementation of individualized treatment plans are recommended.
Keywords: Maternal; Neonatal; Pregnancy; Pregnancy outcome; Rheumatic disease; Rheumatoid arthritis; Systemic lupus erythematous.
© Federation of Obstetric & Gynecological Societies of India 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
Conflict of interest statement
Conflict of InterestThe authors declare that they have no competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Similar articles
-
Multiple-micronutrient supplementation for women during pregnancy.Cochrane Database Syst Rev. 2017 Apr 13;4(4):CD004905. doi: 10.1002/14651858.CD004905.pub5. Cochrane Database Syst Rev. 2017. Update in: Cochrane Database Syst Rev. 2019 Mar 14;3:CD004905. doi: 10.1002/14651858.CD004905.pub6. PMID: 28407219 Free PMC article. Updated.
-
Techniques of monitoring blood glucose during pregnancy for women with pre-existing diabetes.Cochrane Database Syst Rev. 2017 Jun 11;6(6):CD009613. doi: 10.1002/14651858.CD009613.pub3. Cochrane Database Syst Rev. 2017. Update in: Cochrane Database Syst Rev. 2019 May 23;5:CD009613. doi: 10.1002/14651858.CD009613.pub4. PMID: 28602020 Free PMC article. Updated.
-
Metformin for women who are overweight or obese during pregnancy for improving maternal and infant outcomes.Cochrane Database Syst Rev. 2018 Jul 24;7(7):CD010564. doi: 10.1002/14651858.CD010564.pub2. Cochrane Database Syst Rev. 2018. PMID: 30039871 Free PMC article.
-
Progestogen for preventing miscarriage in women with recurrent miscarriage of unclear etiology.Cochrane Database Syst Rev. 2025 Jun 11;6(6):CD003511. doi: 10.1002/14651858.CD003511.pub6. Cochrane Database Syst Rev. 2025. PMID: 40497447 Review.
-
Gestational weight gain below instead of within the guidelines per class of maternal obesity: a systematic review and meta-analysis of obstetrical and neonatal outcomes.Am J Obstet Gynecol MFM. 2022 Sep;4(5):100682. doi: 10.1016/j.ajogmf.2022.100682. Epub 2022 Jun 18. Am J Obstet Gynecol MFM. 2022. PMID: 35728780
References
-
- Sugawara E, Kato M, Fujieda Y, Oku K, Bohgaki T, Yasuda S, et al. Pregnancy outcomes in women with rheumatic diseases: a real-world observational study in Japan. Lupus. 2019;28(12):1407–16. - PubMed
-
- Carvalheiras G, Faria R, Braga J, Vasconcelos C. Fetal outcome in autoimmune diseases. Autoimmun Rev. 2012;11(6–7):A520–30. - PubMed
-
- Sieiro Santos C, Moriano Morales C, Álvarez Castro C, González Fernández I, Díez ÁE. Factors associated with adverse pregnancy outcomes in patients with systemic lupus erythematosus. Musculoskeletal Care. 2022;20(4):917–25. - PubMed
-
- Spinillo A, Beneventi F, Ramoni V, Caporali R, Locatelli E, Simonetta M, et al. Prevalence and significance of previously undiagnosed rheumatic diseases in pregnancy. Ann Rheum Dis. 2012;71(6):918–23. - PubMed